Tags

Type your tag names separated by a space and hit enter

Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia.
Infect Drug Resist. 2021; 14:2667-2674.ID

Abstract

Background

The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study.

Case Description

A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia.

Conclusion

The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.

Authors+Show Affiliations

Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Schulich School of Medical and Dentistry-Honour Specialization in Interdisciplinary Medical Science and Major in Pharmacology, Western University, London, Ontario, Canada.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Critical Care Medicine, Langfang Fourth Hospital, Langfang, Hebei, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.Department of Respiratory Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei, 065000, People's Republic of China.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

34285519

Citation

Liu, Zheng, et al. "Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia." Infection and Drug Resistance, vol. 14, 2021, pp. 2667-2674.
Liu Z, Shi F, Liu JX, et al. Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia. Infect Drug Resist. 2021;14:2667-2674.
Liu, Z., Shi, F., Liu, J. X., Liu, J. Q., Li, J., Wang, Q., Wang, H., Gao, C. L., Li, J. M., & Zhao, D. F. (2021). Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia. Infection and Drug Resistance, 14, 2667-2674. https://doi.org/10.2147/IDR.S314938
Liu Z, et al. Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia. Infect Drug Resist. 2021;14:2667-2674. PubMed PMID: 34285519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia. AU - Liu,Zheng, AU - Shi,Fang, AU - Liu,Jun-Xia, AU - Liu,Jia-Qi, AU - Li,Jing, AU - Wang,Qian, AU - Wang,Hui, AU - Gao,Chang-Lan, AU - Li,Jian-Min, AU - Zhao,Dong-Fang, Y1 - 2021/07/12/ PY - 2021/04/12/received PY - 2021/06/24/accepted PY - 2021/7/21/entrez PY - 2021/7/22/pubmed PY - 2021/7/22/medline KW - COVID-19 pneumonia KW - clinical characteristics KW - corticosteroids KW - cytokine storm SP - 2667 EP - 2674 JF - Infection and drug resistance JO - Infect Drug Resist VL - 14 N2 - Background: The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study. Case Description: A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia. Conclusion: The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy. SN - 1178-6973 UR - https://www.unboundmedicine.com/medline/citation/34285519/Clinical_Efficacy_of_Corticosteroids_in_the_Early_Stages_of_Deterioration_in_COVID-19_Pneumonia. L2 - https://dx.doi.org/10.2147/IDR.S314938 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.